Anzeige
Mehr »
Samstag, 06.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A402U5 | ISIN: US36254L3087 | Ticker-Symbol: OXIA
NASDAQ
05.09.25 | 19:39
0,900 US-Dollar
-1,32 % -0,012
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
GT BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
GT BIOPHARMA INC 5-Tage-Chart

Aktuelle News zur GT BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.08.GT Biopharma, Inc. - 8-K, Current Report1
14.08.GT Biopharma reports Q2 results2
14.08.GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2025 Financial Results133GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and...
► Artikel lesen
GT BIOPHARMA Aktie jetzt für 0€ handeln
11.08.GT Biopharma begins dosing in cohort 3 of cancer treatment trial1
11.08.GT Biopharma, Inc.: GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2193The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe...
► Artikel lesen
24.07.GT Biopharma, Inc. - 8-K, Current Report2
27.06.GT Biopharma, Inc. - S-1/A, General form for registration of securities3
13.06.GT Biopharma appoints David Mun-Gavin to board of directors8
13.06.GT Biopharma, Inc.: GT Biopharma Appoints New Member to its Board of Directors1
11.06.GT Biopharma registers 120.6M shares for resale by selling stockholders2
11.06.GT Biopharma, Inc. - S-1, General form for registration of securities1
11.06.GT Biopharma, Inc. - 8-K, Current Report1
27.05.GT Biopharma, Inc. - 8-K, Current Report4
19.05.Stocks in Play: GT Biopharma, Inc.1
19.05.GT Biopharma advances to next trial phase for cancer therapy3
19.05.GT Biopharma schreitet zur nächsten Testphase für Krebstherapie voran3
19.05.GT Biopharma, Inc.: GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals225Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results...
► Artikel lesen
19.05.EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results3
15.05.GT Biopharma, Inc. - 10-Q, Quarterly Report1
15.05.GT Biopharma appoints new board member1
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1